. 2021 Jun 26;225(3):289.e1–289.e17. doi: 10.1016/j.ajog.2021.05.014

Table 3.

Association between COVID-19 and preeclampsia according to time elapsed between COVID-19 diagnosis and birth

Time between COVID-19 diagnosis and birth	n (%)	All women	Nulliparous	Parous
Unadjusted
No COVID-19 diagnosis	1402 (68.1)	Ref	Ref	Ref
COVID-19 diagnosis, within 7 d of birth or postnatally	426 (20.7)	2.28 (1.57–3.32)^a	2.51 (1.51–4.18)^a	2.10 (1.21–3.62)^a
COVID-19 diagnosis ≥7 d before birth	232 (11.3)	1.07 (0.57–2.01)	0.96 (0.35–2.66)	1.20 (0.54–2.68)
Adjusted^b
No COVID-19 diagnosis	1402 (68.1)	Ref	Ref	Ref
COVID-19 diagnosis, within 7 d of birth or postnatally	426 (20.7)	2.12 (1.44–3.11)^a	2.36 (1.40–3.98)^a	1.83 (1.04–3.21)^a
COVID-19 diagnosis ≥7 d before birth	232 (11.3)	0.99 (0.55–1.79)	0.74 (0.31–1.80)	1.21 (0.55–2.66)

The total numbers reflect the number of participants with complete outcome and covariate data in the final models.

Ref, reference group.

Papageorghiou et al. Preeclampsia and COVID-19. Am J Obstet Gynecol 2021.

P<.05

Adjusted for maternal age, previous parity (nulliparous vs parous), tobacco use during pregnancy, overweight status (normal, underweight, overweight, or obese), or history of diabetes, cardiac disease, hypertension, kidney disease, or history of adverse pregnancy outcomes.